Literature DB >> 11056333

Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen. results Of a double-blind randomised phase III trial.

M Kaufmann1, E Bajetta, L Y Dirix, L E Fein, S E Jones, J Cervek, C Fowst, A Polli, E Di Salle, G Massimini, G Piscitelli.   

Abstract

Exemestane is an aromatase inactivator. 769 Postmenopausal women with advanced breast cancer who had failed on tamoxifen were randomised to exemestane or megoestrol acetate in this double-blind trial. Objective response rate was similar between treatments. Median time to progression, time to treatment failure and overall survival was significantly longer with exemestane. Drug-related withdrawals and drug-related deaths were more common with megoestrol acetate.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11056333     DOI： 10.1016/s0959-8049(00)00240-9

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


  5 in total

Review 1.  Recent Progress in the Discovery of Next Generation Inhibitors of Aromatase from the Structure-Function Perspective.

Authors:  Debashis Ghosh; Jessica Lo; Chinaza Egbuta
Journal:  J Med Chem       Date:  2016-01-19       Impact factor: 7.446

Review 2.  Comparative tolerability of first-generation selective estrogen receptor modulators in breast cancer treatment and prevention.

Authors:  M G Curtis
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 3.  Efficacy and economics of hormonal therapies for advanced breast cancer.

Authors:  Michael S Simon; Dina Ibrahim; Lisa Newman; Miron Stano
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 4.  Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.

Authors:  Lorna Gibson; David Lawrence; Claire Dawson; Judith Bliss
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

5.  A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer.

Authors:  Shannon Cope; Jie Zhang; Stephen Saletan; Brielan Smiechowski; Jeroen P Jansen; Peter Schmid
Journal:  BMC Med       Date:  2014-06-05       Impact factor: 8.775
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.